220 related articles for article (PubMed ID: 24944644)
1. Action of melatonin on squamous cell carcinoma and other tumors of the oral cavity (Review).
Cutando A; López-Valverde A; DE Vicente J; Gimenez JL; Carcía IA; DE Diego RG
Oncol Lett; 2014 Apr; 7(4):923-926. PubMed ID: 24944644
[TBL] [Abstract][Full Text] [Related]
2. Melatonin and cancer: current knowledge and its application to oral cavity tumours.
Cutando A; Aneiros-Fernández J; Aneiros-Cachaza J; Arias-Santiago S
J Oral Pathol Med; 2011 Sep; 40(8):593-7. PubMed ID: 21284745
[TBL] [Abstract][Full Text] [Related]
3. Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth.
Hill SM; Cheng C; Yuan L; Mao L; Jockers R; Dauchy B; Blask DE
Curr Aging Sci; 2013 Feb; 6(1):125-33. PubMed ID: 23895529
[TBL] [Abstract][Full Text] [Related]
4. A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity.
Cutando A; Aneiros-Fernández J; López-Valverde A; Arias-Santiago S; Aneiros-Cachaza J; Reiter RJ
Arch Oral Biol; 2011 Oct; 56(10):944-50. PubMed ID: 21459362
[TBL] [Abstract][Full Text] [Related]
5. Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy [Biochimie 200 (2022) 44-59].
Targhazeh N; Reiter RJ; Rahimi M; Qujeq D; Yousefi T; Shahavi MH; Mir SM
Biochimie; 2022 Sep; 200():44-59. PubMed ID: 35618158
[No Abstract] [Full Text] [Related]
6. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo.
Winczyk K; Pawlikowski M; Lawnicka H; Kunert-Radek J; Spadoni G; Tarzia G; Karasek M
Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():50-4. PubMed ID: 12019352
[TBL] [Abstract][Full Text] [Related]
7. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer.
Winczyk K; Pawlikowski M; Guerrero JM; Karasek M
Tumour Biol; 2002; 23(5):298-302. PubMed ID: 12595746
[TBL] [Abstract][Full Text] [Related]
8. Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy.
Targhazeh N; Reiter RJ; Rahimi M; Qujeq D; Yousefi T; Shahavi MH; Mir SM
Biochimie; 2022 Nov; 202():34-48. PubMed ID: 35752221
[TBL] [Abstract][Full Text] [Related]
9. Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts.
Knower KC; To SQ; Takagi K; Miki Y; Sasano H; Simpson ER; Clyne CD
Breast Cancer Res Treat; 2012 Apr; 132(2):765-71. PubMed ID: 22237979
[TBL] [Abstract][Full Text] [Related]
10. Melatonin.
Mor M; Plazzi PV; Spadoni G; Tarzia G
Curr Med Chem; 1999 Jun; 6(6):501-18. PubMed ID: 10213796
[TBL] [Abstract][Full Text] [Related]
11. Growth-inhibitory activity of melatonin on murine foregastric carcinoma cells in vitro and the underlying molecular mechanism.
Xu L; Liu H; Zhang H; Wang RX; Song J; Zhou RX
Anat Rec (Hoboken); 2013 Jun; 296(6):914-20. PubMed ID: 23564716
[TBL] [Abstract][Full Text] [Related]
12. Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro.
Winczyk K; Fuss-Chmielewska J; Lawnicka H; Pawlikowski M; Karasek M
Neuro Endocrinol Lett; 2009; 30(5):657-62. PubMed ID: 20035258
[TBL] [Abstract][Full Text] [Related]
13. A Review on Melatonin's Effects in Cancer: Potential Mechanisms.
Hanikoglu A; Kucuksayan E; Akduman RC; Ozben T
Anticancer Agents Med Chem; 2018; 18(7):985-992. PubMed ID: 29173185
[TBL] [Abstract][Full Text] [Related]
14. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
15. Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin.
Hill SM; Cheng C; Yuan L; Mao L; Jockers R; Dauchy B; Frasch T; Blask DE
Breast Cancer Res Treat; 2011 May; 127(1):91-8. PubMed ID: 20549340
[TBL] [Abstract][Full Text] [Related]
16. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for melatonin in supportive care?
Lissoni P
Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
[TBL] [Abstract][Full Text] [Related]
18. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):198-200. PubMed ID: 17451889
[TBL] [Abstract][Full Text] [Related]
19. Melatonin downregulates nuclear receptor RZR/RORγ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells
Wang RX; Liu H; Xu L; Zhang H; Zhou RX
Oncol Lett; 2016 Aug; 12(2):897-903. PubMed ID: 27446366
[TBL] [Abstract][Full Text] [Related]
20. Melatonin anticancer effects: review.
Di Bella G; Mascia F; Gualano L; Di Bella L
Int J Mol Sci; 2013 Jan; 14(2):2410-30. PubMed ID: 23348932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
